CA2909645A1 - Laser assisted periodontium and osseus regeneration protocol - Google Patents
Laser assisted periodontium and osseus regeneration protocolInfo
- Publication number
- CA2909645A1 CA2909645A1 CA2909645A CA2909645A CA2909645A1 CA 2909645 A1 CA2909645 A1 CA 2909645A1 CA 2909645 A CA2909645 A CA 2909645A CA 2909645 A CA2909645 A CA 2909645A CA 2909645 A1 CA2909645 A1 CA 2909645A1
- Authority
- CA
- Canada
- Prior art keywords
- substrate
- periodontal pocket
- periodontium
- sulcus
- amino acids
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 210000004261 periodontium Anatomy 0.000 title claims abstract description 18
- 230000008929 regeneration Effects 0.000 title description 8
- 238000011069 regeneration method Methods 0.000 title description 8
- 239000000758 substrate Substances 0.000 claims abstract description 65
- 238000000034 method Methods 0.000 claims abstract description 25
- 208000024693 gingival disease Diseases 0.000 claims abstract description 14
- 238000011282 treatment Methods 0.000 claims description 30
- 239000000203 mixture Substances 0.000 claims description 17
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims description 14
- 230000035876 healing Effects 0.000 claims description 13
- 239000001506 calcium phosphate Substances 0.000 claims description 11
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 11
- 229940078499 tricalcium phosphate Drugs 0.000 claims description 11
- 229910000391 tricalcium phosphate Inorganic materials 0.000 claims description 11
- 235000019731 tricalcium phosphate Nutrition 0.000 claims description 11
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 10
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 claims description 10
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 claims description 10
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 10
- 235000020776 essential amino acid Nutrition 0.000 claims description 10
- 239000003797 essential amino acid Substances 0.000 claims description 10
- 239000013078 crystal Substances 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 241000894006 Bacteria Species 0.000 claims description 8
- 229910019142 PO4 Inorganic materials 0.000 claims description 8
- 235000021317 phosphate Nutrition 0.000 claims description 8
- 150000003013 phosphoric acid derivatives Chemical class 0.000 claims description 8
- 239000008223 sterile water Substances 0.000 claims description 8
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims description 7
- 229960005305 adenosine Drugs 0.000 claims description 7
- 230000000740 bleeding effect Effects 0.000 claims description 7
- 229910052588 hydroxylapatite Inorganic materials 0.000 claims description 7
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 claims description 7
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims description 6
- 239000008280 blood Substances 0.000 claims description 6
- 210000004369 blood Anatomy 0.000 claims description 6
- 230000017531 blood circulation Effects 0.000 claims description 6
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 6
- 239000004475 Arginine Substances 0.000 claims description 5
- 239000005711 Benzoic acid Substances 0.000 claims description 5
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 claims description 5
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 claims description 5
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 5
- 239000004471 Glycine Substances 0.000 claims description 5
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 5
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 5
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 5
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 5
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 5
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 5
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 5
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 5
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 5
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 5
- 239000004472 Lysine Substances 0.000 claims description 5
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 5
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 5
- 239000004473 Threonine Substances 0.000 claims description 5
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 5
- 235000004279 alanine Nutrition 0.000 claims description 5
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 5
- 229940009098 aspartate Drugs 0.000 claims description 5
- 235000010233 benzoic acid Nutrition 0.000 claims description 5
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 claims description 5
- 229930195712 glutamate Natural products 0.000 claims description 5
- 229940029575 guanosine Drugs 0.000 claims description 5
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 5
- 229960000310 isoleucine Drugs 0.000 claims description 5
- 229930182817 methionine Natural products 0.000 claims description 5
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 5
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 claims description 5
- 229940045145 uridine Drugs 0.000 claims description 5
- 239000004474 valine Substances 0.000 claims description 5
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 claims description 4
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 claims description 4
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 4
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 claims description 4
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 4
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 4
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 claims description 4
- 229960004373 acetylcholine Drugs 0.000 claims description 4
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 claims description 4
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 claims description 4
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 3
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 3
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 claims description 3
- 239000004227 calcium gluconate Substances 0.000 claims description 3
- 229960004494 calcium gluconate Drugs 0.000 claims description 3
- 235000013927 calcium gluconate Nutrition 0.000 claims description 3
- 239000000920 calcium hydroxide Substances 0.000 claims description 3
- 229910001861 calcium hydroxide Inorganic materials 0.000 claims description 3
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 claims description 3
- 210000000078 claw Anatomy 0.000 claims description 3
- 239000000576 food coloring agent Substances 0.000 claims description 3
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims description 3
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 claims description 3
- 229960002216 methylparaben Drugs 0.000 claims description 3
- 239000011780 sodium chloride Substances 0.000 claims description 3
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 claims description 2
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 claims description 2
- 229960003415 propylparaben Drugs 0.000 claims description 2
- 208000005888 Periodontal Pocket Diseases 0.000 claims 12
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 claims 4
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 claims 4
- 230000001764 biostimulatory effect Effects 0.000 claims 4
- 230000035602 clotting Effects 0.000 claims 4
- 238000010438 heat treatment Methods 0.000 claims 4
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 claims 2
- 238000006073 displacement reaction Methods 0.000 claims 2
- 230000004936 stimulating effect Effects 0.000 claims 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims 1
- 239000001768 carboxy methyl cellulose Substances 0.000 claims 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims 1
- 230000001143 conditioned effect Effects 0.000 claims 1
- 230000000249 desinfective effect Effects 0.000 claims 1
- 229940124274 edetate disodium Drugs 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 238000012423 maintenance Methods 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 230000000087 stabilizing effect Effects 0.000 claims 1
- 238000004659 sterilization and disinfection Methods 0.000 claims 1
- 230000000638 stimulation Effects 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 abstract description 21
- 210000004872 soft tissue Anatomy 0.000 abstract description 20
- 238000001228 spectrum Methods 0.000 abstract description 8
- 208000007536 Thrombosis Diseases 0.000 abstract description 5
- 210000000981 epithelium Anatomy 0.000 abstract description 4
- 230000001172 regenerating effect Effects 0.000 abstract description 3
- 230000000149 penetrating effect Effects 0.000 abstract description 2
- 238000005259 measurement Methods 0.000 description 11
- 230000003239 periodontal effect Effects 0.000 description 10
- 229940024606 amino acid Drugs 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 239000011575 calcium Substances 0.000 description 6
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 229960005069 calcium Drugs 0.000 description 5
- 229910052791 calcium Inorganic materials 0.000 description 5
- 210000002950 fibroblast Anatomy 0.000 description 5
- 230000008901 benefit Effects 0.000 description 4
- 210000000988 bone and bone Anatomy 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000001243 protein synthesis Methods 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 230000014616 translation Effects 0.000 description 4
- 102100040409 Ameloblastin Human genes 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000037182 bone density Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000001739 density measurement Methods 0.000 description 3
- 108010074702 enamel matrix proteins Proteins 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 208000028169 periodontal disease Diseases 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 230000017423 tissue regeneration Effects 0.000 description 3
- 238000001429 visible spectrum Methods 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- LNQCUTNLHUQZLR-VNPYQEQNSA-N Iridin Natural products O(C)c1c(O)c2C(=O)C(c3cc(OC)c(OC)c(O)c3)=COc2cc1O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 LNQCUTNLHUQZLR-VNPYQEQNSA-N 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- 244000082490 Proboscidea louisianica Species 0.000 description 2
- 235000015926 Proboscidea louisianica ssp. fragrans Nutrition 0.000 description 2
- 235000015925 Proboscidea louisianica subsp. louisianica Nutrition 0.000 description 2
- 235000019096 Proboscidea parviflora Nutrition 0.000 description 2
- 208000008312 Tooth Loss Diseases 0.000 description 2
- -1 Ttyptophan Chemical compound 0.000 description 2
- 230000001133 acceleration Effects 0.000 description 2
- 230000010072 bone remodeling Effects 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 201000001245 periodontitis Diseases 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- FDKWRPBBCBCIGA-REOHCLBHSA-N (2r)-2-azaniumyl-3-$l^{1}-selanylpropanoate Chemical compound [Se]C[C@H](N)C(O)=O FDKWRPBBCBCIGA-REOHCLBHSA-N 0.000 description 1
- 230000002407 ATP formation Effects 0.000 description 1
- 208000010266 Aggressive Periodontitis Diseases 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- FDKWRPBBCBCIGA-UWTATZPHSA-N D-Selenocysteine Natural products [Se]C[C@@H](N)C(O)=O FDKWRPBBCBCIGA-UWTATZPHSA-N 0.000 description 1
- 208000006558 Dental Calculus Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000010478 bone regeneration Effects 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- KIZFHUJKFSNWKO-UHFFFAOYSA-M calcium monohydroxide Chemical compound [Ca]O KIZFHUJKFSNWKO-UHFFFAOYSA-M 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 210000000250 cementoblast Anatomy 0.000 description 1
- 230000005210 cementogenesis Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 208000001277 chronic periodontitis Diseases 0.000 description 1
- 230000001427 coherent effect Effects 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 229940031098 ethanolamine Drugs 0.000 description 1
- 201000005562 gingival recession Diseases 0.000 description 1
- 208000007565 gingivitis Diseases 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- LNQCUTNLHUQZLR-OZJWLQQPSA-N iridin Chemical compound OC1=C(OC)C(OC)=CC(C=2C(C3=C(O)C(OC)=C(O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)C=C3OC=2)=O)=C1 LNQCUTNLHUQZLR-OZJWLQQPSA-N 0.000 description 1
- 108010047623 iridine Proteins 0.000 description 1
- 238000002647 laser therapy Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 230000002956 necrotizing effect Effects 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 210000005009 osteogenic cell Anatomy 0.000 description 1
- 210000002379 periodontal ligament Anatomy 0.000 description 1
- 238000011176 pooling Methods 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000009719 regenerative response Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- ZKZBPNGNEQAJSX-UHFFFAOYSA-N selenocysteine Natural products [SeH]CC(N)C(O)=O ZKZBPNGNEQAJSX-UHFFFAOYSA-N 0.000 description 1
- 235000016491 selenocysteine Nutrition 0.000 description 1
- 229940055619 selenocysteine Drugs 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 235000011121 sodium hydroxide Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/24—Phosphorous; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61C—DENTISTRY; APPARATUS OR METHODS FOR ORAL OR DENTAL HYGIENE
- A61C19/00—Dental auxiliary appliances
- A61C19/06—Implements for therapeutic treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61C—DENTISTRY; APPARATUS OR METHODS FOR ORAL OR DENTAL HYGIENE
- A61C19/00—Dental auxiliary appliances
- A61C19/06—Implements for therapeutic treatment
- A61C19/063—Medicament applicators for teeth or gums, e.g. treatment with fluorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/20—Halogens; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/368—Carboxylic acids; Salts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/41—Amines
- A61K8/416—Quaternary ammonium compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
- A61K8/442—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof substituted by amido group(s)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/606—Nucleosides; Nucleotides; Nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0613—Apparatus adapted for a specific treatment
- A61N5/0624—Apparatus adapted for a specific treatment for eliminating microbes, germs, bacteria on or in the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/067—Radiation therapy using light using laser light
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/81—Preparation or application process involves irradiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0601—Apparatus for use inside the body
- A61N5/0603—Apparatus for use inside the body for treatment of body cavities
- A61N2005/0606—Mouth
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Birds (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Pathology (AREA)
- Radiology & Medical Imaging (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Biochemistry (AREA)
- Dentistry (AREA)
- Optics & Photonics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- Organic Chemistry (AREA)
- Dental Tools And Instruments Or Auxiliary Dental Instruments (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Laser Surgery Devices (AREA)
Abstract
A method of treating gum disease using a soft tissue diode laser which generates a beam of light having a wavelength in the visible portion of the electromagnetic spectrum (400nm - 700nm) at a laser power of 0.5 to 1.2 watts, used with intermittent stops to control tissue temperature, to decontaminate the gum tissue and biostimulate the periodontium nonsurgically when used with a substrate, thus preventing the long junctional epithelium from migrating into the sulcus, preserving tissue height, and regenerating periodontium, the method comprising: placing the tip of the laser inside the sulcus; penetrating the entire sulcus by moving the laser light with intermittent stops to control tissue temperature vertically and horizontally throughout the sulcus; and placing a substrate in the sulcus prior to a blood clot forming, thus regenerating periodontium in the sulcus.
Description
LASER ASSISTED PERIODONTIUM AND OSSEUS REGENERATION PROTOCOL
by Margaret V. Kalmeta CROSS REFERENCES
This application claims priority to United States Continuation-In-Part Patent Application No. 13/864,226 filed April 16, 2013, which claims the benefit of priority under 35 U.S.C. 120 from United States Patent Application No. 13/078,757 filed April 4, 2011, the entire contents of which are herein incorporated by reference.
FIELD OF THE INVENTION
The present invention relates generally to a method of treating gum diseases using a soft tissue diode laser which produces a beam of light having a wavelength in the visible portion of the electromagnetic spectrum (400nm ¨ 700nm). Optionally, the laser light utilizes green wavelength range (520¨ 570 nm) at a laser power of 0.5 to 1.2 watts to treat gum disease.
BACKGROUND OF THE INVENTION
Laser Assisted Periodontium And Osseus Regeneration (LAPOR) is a protocol which is laser assisted with the use of a substrate such as but not limited the LAPOR
periodontal solution, the LAPOR periodontal gel and the LAPOR substrate and thus causes an increase in cell attachment of epithelial cells, gingival fibroblasts, PDL fibroblasts and adhesion of osteogenic cells. This protocol has shown to increase the expression of transcription factors related to the differentiation of osteoblasts/ cementoblasts as well as chondroblasts.
Enhanced cell migration and proliferation appears to lead to accelerated wound fill rates in vitro using PDL fibroblasts, gingival fibroblasts and osteoblast-like cells.
A substrate such as the LAPOR periodontal solution, the LAPOR periodontal gel and the LAPOR substrate, used in the LAPOR protocol, stimulates total protein synthesis and the synthesis of specific extracellular matrix molecules. Studies that evaluate the bone remodeling regulation system indicate that enamel matrix proteins influence this by modulating the OPG and RANK! expression, thus indicating an indirect involvement in the bone remodeling process.
The soft tissue diode laser used produces a beam of light having a wavelength in the visible portion of the electromagnetic spectrum (400nm ¨ 700nm). Optionally, a beam of light having a wavelength in the green wavelength range (520 ¨ 570 nm) at a laser power of 0.5 to 1 .2 watts is used in the LAPOR protocol. It has been shown by the LAPOR protocol to biostimulate the healing and regenerative processes of the periodontium, including the biostimulation of new bone and its supporting elements. Previous studies have shown a positive healing effect of low power laser therapy (infrared range of a soft tissue diode laser) on tissue repair. Low power lasers, in the infrared range, have been shown to positively affect several indices of tissue repair.
They biostimulate wound healing by acceleration of collagen synthesis, acceleration of inflammation, decrease of healing time, acquisition of strength. They biostimulate regeneration of tissue via elevated metabolic indices of ATP synthesis, elevated fibroblast proliferation, elevated collagen synthesis and increased indices of biomechanical aspects of tissue healing. The soft tissue diode laser used in the LAPOR protocol, biostimulates the healing response of the periodontium nonsurgically, and biostimulates the tissue regeneration of the periodontium, nonsurgically, and prevents long junctional epithelium from migrating downwards into the sulcus (a biomechanical aspect of tissue healing), thereby preserving the tissue height. A soft tissue diode laser used in the LAPOR protocol helps a substrate such as but not limited to enamel matrix proteins to stimulate total protein synthesis and the synthesis of extracellular matrix molecules, nonsurgically.
SUMMARY OF THE INVENTION
In an exemplary embodiment of the present invention, there is disclosed a method of treating gum disease using a soft tissue diode laser which generates a beam of light having a wavelength in the visible portion of the electromagnetic spectrum (400nm ¨
700nm). Optionally, a beam of light having a wavelength in the green range (520 ¨ 570 urn) at a laser power of 0.5 to
by Margaret V. Kalmeta CROSS REFERENCES
This application claims priority to United States Continuation-In-Part Patent Application No. 13/864,226 filed April 16, 2013, which claims the benefit of priority under 35 U.S.C. 120 from United States Patent Application No. 13/078,757 filed April 4, 2011, the entire contents of which are herein incorporated by reference.
FIELD OF THE INVENTION
The present invention relates generally to a method of treating gum diseases using a soft tissue diode laser which produces a beam of light having a wavelength in the visible portion of the electromagnetic spectrum (400nm ¨ 700nm). Optionally, the laser light utilizes green wavelength range (520¨ 570 nm) at a laser power of 0.5 to 1.2 watts to treat gum disease.
BACKGROUND OF THE INVENTION
Laser Assisted Periodontium And Osseus Regeneration (LAPOR) is a protocol which is laser assisted with the use of a substrate such as but not limited the LAPOR
periodontal solution, the LAPOR periodontal gel and the LAPOR substrate and thus causes an increase in cell attachment of epithelial cells, gingival fibroblasts, PDL fibroblasts and adhesion of osteogenic cells. This protocol has shown to increase the expression of transcription factors related to the differentiation of osteoblasts/ cementoblasts as well as chondroblasts.
Enhanced cell migration and proliferation appears to lead to accelerated wound fill rates in vitro using PDL fibroblasts, gingival fibroblasts and osteoblast-like cells.
A substrate such as the LAPOR periodontal solution, the LAPOR periodontal gel and the LAPOR substrate, used in the LAPOR protocol, stimulates total protein synthesis and the synthesis of specific extracellular matrix molecules. Studies that evaluate the bone remodeling regulation system indicate that enamel matrix proteins influence this by modulating the OPG and RANK! expression, thus indicating an indirect involvement in the bone remodeling process.
The soft tissue diode laser used produces a beam of light having a wavelength in the visible portion of the electromagnetic spectrum (400nm ¨ 700nm). Optionally, a beam of light having a wavelength in the green wavelength range (520 ¨ 570 nm) at a laser power of 0.5 to 1 .2 watts is used in the LAPOR protocol. It has been shown by the LAPOR protocol to biostimulate the healing and regenerative processes of the periodontium, including the biostimulation of new bone and its supporting elements. Previous studies have shown a positive healing effect of low power laser therapy (infrared range of a soft tissue diode laser) on tissue repair. Low power lasers, in the infrared range, have been shown to positively affect several indices of tissue repair.
They biostimulate wound healing by acceleration of collagen synthesis, acceleration of inflammation, decrease of healing time, acquisition of strength. They biostimulate regeneration of tissue via elevated metabolic indices of ATP synthesis, elevated fibroblast proliferation, elevated collagen synthesis and increased indices of biomechanical aspects of tissue healing. The soft tissue diode laser used in the LAPOR protocol, biostimulates the healing response of the periodontium nonsurgically, and biostimulates the tissue regeneration of the periodontium, nonsurgically, and prevents long junctional epithelium from migrating downwards into the sulcus (a biomechanical aspect of tissue healing), thereby preserving the tissue height. A soft tissue diode laser used in the LAPOR protocol helps a substrate such as but not limited to enamel matrix proteins to stimulate total protein synthesis and the synthesis of extracellular matrix molecules, nonsurgically.
SUMMARY OF THE INVENTION
In an exemplary embodiment of the present invention, there is disclosed a method of treating gum disease using a soft tissue diode laser which generates a beam of light having a wavelength in the visible portion of the electromagnetic spectrum (400nm ¨
700nm). Optionally, a beam of light having a wavelength in the green range (520 ¨ 570 urn) at a laser power of 0.5 to
2 1.2 watts is used to decontaminate the gum tissue and to biostimulate healing and regenerate the periodontium (including cementurn of the root surface), thus preventing long junctional epithelium from migrating downwards into the sulcus and thereby preserving the tissue height.
The soft tissue diode laser also biostimulates the healing and regenerative response induced by a substrate, i.e. the LAPOR periodontal solution, the LAPOR periodontal gel and the LAPOR
periodontal substrate, the method comprising: 1) placing the laser inside the sulcus; 2) penetrating the entire sulcus by moving the laser light intermittently vertically and horizontally throughout the sulcus; and 3) placing the substrate in the sulcus prior to a blood clot forming (which then increases cell attachment, adhesion, migration and proliferation).
In another embodiment of the present invention, there is disclosed a root/bone/cartilage conditioner comprised of EDTA 15%, calcium gluconate 20%, methylparaben, propylparaben, Ethanolamine as a buffering agent, carboxymethyleellulose, and green food coloring and sterile water.
In still another embodiment of the present invention, there is disclosed a first substrate comprised of: a combination of mono or disodium phosphate and sodium hydroxide in solution with a sodium content of 11mg/100g; 60% water; 9% Lysine; 9% Proline; 9% all other essential amino acids wherein the amino acids are chosen from the group consisting of Isoleucine, Leucine, Methionine, Phenylalanine, Threonine, Ttyptophan, Valine, Histadine, Asparagine and Selenocysteine; 2% of all other non-essential amino acids wherein the amino acids are chosen from the group consisting of Alanine, Arginine, Aspartate, Cysteine, Glutamate, Glutamine, Glycine, Serine, Tyrosine and Pyrrolsine; 6.9% free bases wherein the free bases are chosen from the group consisting of adenosine, uridine, guanosine, iridin and cytidine; 2% phosphates wherein the phosphates are chosen from the group consisting of ADP, ATP and acetycholine;
and 1% benzoic acid at a pH of 7.45.
In still another embodiment of the present invention, there is disclosed a second substrate comprised of: tricalcium phosphate wherein the tricalcium phosphate is precipitated with calcium hydroxide/Claw oil; and hydroxyapatite crystals.
The soft tissue diode laser also biostimulates the healing and regenerative response induced by a substrate, i.e. the LAPOR periodontal solution, the LAPOR periodontal gel and the LAPOR
periodontal substrate, the method comprising: 1) placing the laser inside the sulcus; 2) penetrating the entire sulcus by moving the laser light intermittently vertically and horizontally throughout the sulcus; and 3) placing the substrate in the sulcus prior to a blood clot forming (which then increases cell attachment, adhesion, migration and proliferation).
In another embodiment of the present invention, there is disclosed a root/bone/cartilage conditioner comprised of EDTA 15%, calcium gluconate 20%, methylparaben, propylparaben, Ethanolamine as a buffering agent, carboxymethyleellulose, and green food coloring and sterile water.
In still another embodiment of the present invention, there is disclosed a first substrate comprised of: a combination of mono or disodium phosphate and sodium hydroxide in solution with a sodium content of 11mg/100g; 60% water; 9% Lysine; 9% Proline; 9% all other essential amino acids wherein the amino acids are chosen from the group consisting of Isoleucine, Leucine, Methionine, Phenylalanine, Threonine, Ttyptophan, Valine, Histadine, Asparagine and Selenocysteine; 2% of all other non-essential amino acids wherein the amino acids are chosen from the group consisting of Alanine, Arginine, Aspartate, Cysteine, Glutamate, Glutamine, Glycine, Serine, Tyrosine and Pyrrolsine; 6.9% free bases wherein the free bases are chosen from the group consisting of adenosine, uridine, guanosine, iridin and cytidine; 2% phosphates wherein the phosphates are chosen from the group consisting of ADP, ATP and acetycholine;
and 1% benzoic acid at a pH of 7.45.
In still another embodiment of the present invention, there is disclosed a second substrate comprised of: tricalcium phosphate wherein the tricalcium phosphate is precipitated with calcium hydroxide/Claw oil; and hydroxyapatite crystals.
3 The more important features of the invention have thus been outlined in order that the more detailed description that follows may be better understood and in order that the present contribution to the art may better be appreciated. Additional features of the invention will be described hereinafter and will form the subject matter of the claims that follow.
Before explaining at least one embodiment of the invention in detail, it is to be understood that the invention is not limited in its application to the details of construction and the arrangements of the components set forth in the following description or illustrated in the drawings. The invention is capable of other embodiments and of being practiced and carried out in various ways. Also it is to be understood that the phraseology and terminology employed herein are for the purpose of description and should not be regarded as limiting.
As such, those skilled in the art will appreciate that the conception, upon which this disclosure is based, may readily be utilized as a basis for the designing of other structures, methods and systems for carrying out the several purposes of the present invention. It is important, therefore, that the claims be regarded as including such equivalent constructions insofar as they do not depart from the spirit and scope of the present invention.
The foregoing has outlined, rather broadly, the preferred feature of the present invention so that those skilled in the art may better understand the detailed description of the invention that follows. Additional features of the invention will be described hereinafter that form the subject of the claims of the invention. Those skilled in the art should appreciate that they can readily use the disclosed conception and specific embodiment as a basis for designing or modifying other structures for carrying out the same purposes of the present invention and that such other structures do not depart from the spirit and scope of the invention in its broadest form.
BRIEF DESCRIPTION OF THE DRAWINGS
Other aspects, features, and advantages of the present invention will become more fully apparent from the following detailed description, the appended claim, and the accompanying drawings in which similar elements are given similar reference numerals.
Before explaining at least one embodiment of the invention in detail, it is to be understood that the invention is not limited in its application to the details of construction and the arrangements of the components set forth in the following description or illustrated in the drawings. The invention is capable of other embodiments and of being practiced and carried out in various ways. Also it is to be understood that the phraseology and terminology employed herein are for the purpose of description and should not be regarded as limiting.
As such, those skilled in the art will appreciate that the conception, upon which this disclosure is based, may readily be utilized as a basis for the designing of other structures, methods and systems for carrying out the several purposes of the present invention. It is important, therefore, that the claims be regarded as including such equivalent constructions insofar as they do not depart from the spirit and scope of the present invention.
The foregoing has outlined, rather broadly, the preferred feature of the present invention so that those skilled in the art may better understand the detailed description of the invention that follows. Additional features of the invention will be described hereinafter that form the subject of the claims of the invention. Those skilled in the art should appreciate that they can readily use the disclosed conception and specific embodiment as a basis for designing or modifying other structures for carrying out the same purposes of the present invention and that such other structures do not depart from the spirit and scope of the invention in its broadest form.
BRIEF DESCRIPTION OF THE DRAWINGS
Other aspects, features, and advantages of the present invention will become more fully apparent from the following detailed description, the appended claim, and the accompanying drawings in which similar elements are given similar reference numerals.
4 FIG. 1 shows an X-Ray view of a patient's teeth before treatment with a soft tissue diode laser before a substrate has been applied.
FIG. 2-7 show X-Ray views of the lower teeth of FIG. 1 after treatment with a soft tissue diode laser after treatment with a substrate.
FIG. 8 shows an X-Ray view of the upper teeth before treatment with a soft tissue diode laser after treatment with a substrate.
Fig. 9 shows an X-ray view of the upper teeth of Fig. 8 after treatment with a soft tissue diode laser after treatment with a substrate.
Fig. 10 shows a flow diagram of a method of using a soft tissue diode laser to treat gum disease in accordance with the principles of the invention.
Fig. 11 shows bone density measurements for tooth 15 of a patient at 12 loci on the tooth following treatment with a soft tissue diode laser and a substrate over time.
Fig. 12 shows bone density measurements for tooth 28 of a patient at 17 loci on the tooth following treatment with a soft tissue diode laser and a substrate over time.
Fig. 13 shows bone density measurements for tooth 2, tooth 3 and tooth 15 of a patient at 3 loci per tooth following treatment with a soft tissue diode laser and a substrate over time.
Fig. 14 shows X-rays of tooth 15 of a patient from which measurements shown in Fig. 11 were collected. (a) shows tooth 15 before treatment. (b) shows tooth 15 at the October 2011 measurement following three treatments.
Fig. 15 shows X-rays of tooth 28 of a patient from which measurements shown in Fig. 12 were collected. (a) shows tooth 28 before treatment. (b) shows tooth 28 at the January 2011 measurement following four treatments.
Fig. 16 shows a panoramic X-ray of tooth 2, tooth 3 and tooth 15 of a patient from which measurements shown in Fig. 13 were collected. (a) shows the teeth before treatment. (b) shows the teeth at the July 2011 measurement.
DETAILED DESCRIPTION OF THE INVENTION
Definitions As used herein, the term "gum disease" means periodontal disease which can lead to tooth loss and/or other health problems. Examples of periodontal disease include gingivitis, aggressive periodontitis, chronic periodontitis, periodontitis as a manifestation of systemic diseases, and necrotizing periodontal disease.
As used herein, the term "patient" means any individual suffering from a disease of the gums and in need of treatment for said gum disease.
As used herein, the term "locus" means an exact point of measurement within the sulcus or the immediate surrounding area.
As used herein, the term "substrate mixture" means the mixture of the first substrate and the second substrate disclosed herein for treatment of gum disease.
As used herein, the term "bone regeneration" means increasing the density of calcium at specific loci in or around the sulcus.
As used herein, the term "calcium density" means the measurement of calcium mass around a given loci.
The LAPOR protocol can be used in the treatment of gum disease by combining the most effective methods of treatment with the use of a special laser. Approximately 66% of the United States population has some form of gum disease. But many avoid seeking treatment because of the discomfort that often results from gum surgery. LAPOR provides a new choice. The LAPOR
protocol is a treatment that is more effective as traditional periodontal surgery, and it is much more beneficial to the patient both in the short term and in the long run.
The LAPOR protocol takes only about an hour and only two short follow-up visits.
Patients enjoy no downtime with recovery taking only 24 hours. This makes immediate return to work both possible and comfortable.
After having the LAPOR protocol performed, gum recession is minimal to none when compared to that which most often follows normal periodontal surgery. This, combined with new cementum formation on the roots, bone formation in previous defects, periodontal ligament formation tooth loss.
The special type of laser used in the LAPOR protocol is the diode, a semiconductor coherent light beam used on soft tissues. The laser light used has a wavelength in the visible portion of the electromagnetic spectrum, between 400nm ¨ 700nm wavelength.
Optionally, the green range (520 ¨ 570 nrn) of the visible spectrum is utilized at a laser power of 0.5 to 1.2 watts, which disinfects the site, leaving the gum tissue bacteria free, and biostimulates healing; in conjunction with treatment with a substrate, the laser bio stimulates regeneration of the peiiodontium. Traditional periodontal therapy removes tissue height of a tooth to reduce the pocket depths. The LAPOR protocol is a regenerative procedure. The patient does not lose tissue volume. Tissue volume is increased and bone is regenerated.
The green wavelength is ideally suited for soft tissue procedures since it is highly absorbed by hemoglobin and melanin. This gives the diode laser the ability to, in this case, target the soft tissues.
The use of the diode laser in conjunction with routine scaling and root planning is more effective than scaling and root planning alone. It enhances the speed and extent of the patients gingival healing and postoperative comfort. This is accomplished through laser bacterial reduction and biostimulation with a laser light having a wavelength in the visible portion of the electromagnetic spectrum, between 400mn 700nrn wavelength. Optionally, the green range (520 ¨ 570 nm) of the visible spectrum is utilized at a laser power of 0.5 to 1.2 watts.
Referring to FIG. 10, there is disclosed a method 10 of using a soft tissue diode laser which produces a beam of light, used intermittently, having a wavelength in the visible portion of the electromagnetic spectrum, between 400nm ¨ 700nm wavelength. Optionally, the green range (520 ¨ 570 nm) of the visible spectrum is utilized at a laser power of 0.5 to 1.2 watts to treat gum disease. Starting at block 12, a perio probe determines the degree of excessive pocket depth and thus helps the dentist better identify diseased tissue and areas of bacterial infection.
The dentist removes tartar from the root surface using an ultrasonic scaler and hand instruments, block 14. This action by the dentist helps stimulate a healing response in the sulcus by opening up the capillaries upon scaling. Going to block 18, the laser tip is placed inside the sulcus and a continuous light beam with intermittent stops for tissue temperature control is allowed to penetrate the entire sulcus by moving the tip vertically and horizontally throughout the sulcus.
The laser tip is cut at a 45 degree angle during the first pass. The laser is cut at the opposite 45 degree angle during the second pass. This allows for the laser beam to penetrate the existing periodontium to decontaminate the tissue, as the heat of the targeted laser light kills the bacteria.
This also allows for biostimulation of the sulcular contents. At block 20, the dentist scales the sulcular area and root surfaces once again to induce a healing response through renewed blood flow. Going to block 22, a substrate, such as but not limited to enamel matrix proteins, is then placed in the sulcus of the tooth prior to the blood clot forming and at block 24, a blood clot is carefully allowed to form by gently helping patient keep their mouth open for
FIG. 2-7 show X-Ray views of the lower teeth of FIG. 1 after treatment with a soft tissue diode laser after treatment with a substrate.
FIG. 8 shows an X-Ray view of the upper teeth before treatment with a soft tissue diode laser after treatment with a substrate.
Fig. 9 shows an X-ray view of the upper teeth of Fig. 8 after treatment with a soft tissue diode laser after treatment with a substrate.
Fig. 10 shows a flow diagram of a method of using a soft tissue diode laser to treat gum disease in accordance with the principles of the invention.
Fig. 11 shows bone density measurements for tooth 15 of a patient at 12 loci on the tooth following treatment with a soft tissue diode laser and a substrate over time.
Fig. 12 shows bone density measurements for tooth 28 of a patient at 17 loci on the tooth following treatment with a soft tissue diode laser and a substrate over time.
Fig. 13 shows bone density measurements for tooth 2, tooth 3 and tooth 15 of a patient at 3 loci per tooth following treatment with a soft tissue diode laser and a substrate over time.
Fig. 14 shows X-rays of tooth 15 of a patient from which measurements shown in Fig. 11 were collected. (a) shows tooth 15 before treatment. (b) shows tooth 15 at the October 2011 measurement following three treatments.
Fig. 15 shows X-rays of tooth 28 of a patient from which measurements shown in Fig. 12 were collected. (a) shows tooth 28 before treatment. (b) shows tooth 28 at the January 2011 measurement following four treatments.
Fig. 16 shows a panoramic X-ray of tooth 2, tooth 3 and tooth 15 of a patient from which measurements shown in Fig. 13 were collected. (a) shows the teeth before treatment. (b) shows the teeth at the July 2011 measurement.
DETAILED DESCRIPTION OF THE INVENTION
Definitions As used herein, the term "gum disease" means periodontal disease which can lead to tooth loss and/or other health problems. Examples of periodontal disease include gingivitis, aggressive periodontitis, chronic periodontitis, periodontitis as a manifestation of systemic diseases, and necrotizing periodontal disease.
As used herein, the term "patient" means any individual suffering from a disease of the gums and in need of treatment for said gum disease.
As used herein, the term "locus" means an exact point of measurement within the sulcus or the immediate surrounding area.
As used herein, the term "substrate mixture" means the mixture of the first substrate and the second substrate disclosed herein for treatment of gum disease.
As used herein, the term "bone regeneration" means increasing the density of calcium at specific loci in or around the sulcus.
As used herein, the term "calcium density" means the measurement of calcium mass around a given loci.
The LAPOR protocol can be used in the treatment of gum disease by combining the most effective methods of treatment with the use of a special laser. Approximately 66% of the United States population has some form of gum disease. But many avoid seeking treatment because of the discomfort that often results from gum surgery. LAPOR provides a new choice. The LAPOR
protocol is a treatment that is more effective as traditional periodontal surgery, and it is much more beneficial to the patient both in the short term and in the long run.
The LAPOR protocol takes only about an hour and only two short follow-up visits.
Patients enjoy no downtime with recovery taking only 24 hours. This makes immediate return to work both possible and comfortable.
After having the LAPOR protocol performed, gum recession is minimal to none when compared to that which most often follows normal periodontal surgery. This, combined with new cementum formation on the roots, bone formation in previous defects, periodontal ligament formation tooth loss.
The special type of laser used in the LAPOR protocol is the diode, a semiconductor coherent light beam used on soft tissues. The laser light used has a wavelength in the visible portion of the electromagnetic spectrum, between 400nm ¨ 700nm wavelength.
Optionally, the green range (520 ¨ 570 nrn) of the visible spectrum is utilized at a laser power of 0.5 to 1.2 watts, which disinfects the site, leaving the gum tissue bacteria free, and biostimulates healing; in conjunction with treatment with a substrate, the laser bio stimulates regeneration of the peiiodontium. Traditional periodontal therapy removes tissue height of a tooth to reduce the pocket depths. The LAPOR protocol is a regenerative procedure. The patient does not lose tissue volume. Tissue volume is increased and bone is regenerated.
The green wavelength is ideally suited for soft tissue procedures since it is highly absorbed by hemoglobin and melanin. This gives the diode laser the ability to, in this case, target the soft tissues.
The use of the diode laser in conjunction with routine scaling and root planning is more effective than scaling and root planning alone. It enhances the speed and extent of the patients gingival healing and postoperative comfort. This is accomplished through laser bacterial reduction and biostimulation with a laser light having a wavelength in the visible portion of the electromagnetic spectrum, between 400mn 700nrn wavelength. Optionally, the green range (520 ¨ 570 nm) of the visible spectrum is utilized at a laser power of 0.5 to 1.2 watts.
Referring to FIG. 10, there is disclosed a method 10 of using a soft tissue diode laser which produces a beam of light, used intermittently, having a wavelength in the visible portion of the electromagnetic spectrum, between 400nm ¨ 700nm wavelength. Optionally, the green range (520 ¨ 570 nm) of the visible spectrum is utilized at a laser power of 0.5 to 1.2 watts to treat gum disease. Starting at block 12, a perio probe determines the degree of excessive pocket depth and thus helps the dentist better identify diseased tissue and areas of bacterial infection.
The dentist removes tartar from the root surface using an ultrasonic scaler and hand instruments, block 14. This action by the dentist helps stimulate a healing response in the sulcus by opening up the capillaries upon scaling. Going to block 18, the laser tip is placed inside the sulcus and a continuous light beam with intermittent stops for tissue temperature control is allowed to penetrate the entire sulcus by moving the tip vertically and horizontally throughout the sulcus.
The laser tip is cut at a 45 degree angle during the first pass. The laser is cut at the opposite 45 degree angle during the second pass. This allows for the laser beam to penetrate the existing periodontium to decontaminate the tissue, as the heat of the targeted laser light kills the bacteria.
This also allows for biostimulation of the sulcular contents. At block 20, the dentist scales the sulcular area and root surfaces once again to induce a healing response through renewed blood flow. Going to block 22, a substrate, such as but not limited to enamel matrix proteins, is then placed in the sulcus of the tooth prior to the blood clot forming and at block 24, a blood clot is carefully allowed to form by gently helping patient keep their mouth open for
5 minutes, to keep the substrate intact.
The LAPOR protocol is much less invasive than traditional surgery and offers advantages and benefits over its counterpart. Recovery time is much faster because most, if not all, damage to healthy tissue is avoided through the use of more advanced technology.
Because the LAPOR
protocol leaves healthy tissue intact, the height of the gums themselves around the teeth is much better preserved. The LAPOR protocol prevents long junctional epithelium from migrating downwards into the sulcus, thus preserving the tissue height and allowing for the regeneration of the periodontium.
Firstly, the root conditioner is applied to the sulcus. The root conditioner comprises the following at Table 1:
Table 1 Component EDTA 20-25g.
Calcium gluconate 10-20 g.
Methylpara ben .1-.9 g.
Pro pylpa ra be n .01-.1 g.
Ethanolamine 2-8 mis.
Ca rboxymethylce II u lose 2-10 g.
Green food coloring 1-2 drops Sterile water 100 mls.
The conditioner is optionally rinsed out prior to application of additional substrates or laser light. Alternatively, the conditioner is left in the sulcus, with the laser light being applied prior to application of any substrate. In an alternative embodiment, the conditioner is left in with only one substrate applied prior to application of the laser light.
Optionally, the conditioner is left in the sulcus and substrate is added prior to any application of laser light.
The placement of the substrate into the sulcus containing luminesced blood enables the lumineseed blood to coagulate upon the substrate. The substrate contains building blocks for protein synthesis as well as substances used as energy for protein synthesis.
The substrate also contains hard components that are able to be used by the body as a "lattice"
for regeneration.
The substrate also contains a slow release pH increasing agent to increase the pH for optimal regeneration while not "startling" the body such that it will have a negative reaction to the substrate.
Optionally, the liquid substrate is comprised of the following, per 1L of solution, at Table 2:
Table 2 Essential %
Amino Acids Isoleucine 1.125 Leucine 1.125 Methionine 1.125 Phenylalanine 1.125 Threonine 1.125 Tryptophan 1.125 Valine 1.125 Histidine 1.125 Lysine 9 Non Essential %
Amino Acids Alanine 0.25 Arginine 0.25 Aspartate 0.75 Glutamate 0.25 Glycine 0.25 Serine 0.25 Proline 9 Phosphates %
ADP 0.667 ATP 0.667 Acetylcholine 0.667 Free Bases %
Adenosine 1.725 Uridine 1.725 Guanosine 1.725 Cytidine 1.725 Benzoic Acid 1 Sodium 1.1 Chloride Sterile water 60 Total: 100 Optionally, the total sterile water component is adjusted 20% up or down, depending on the desired viscosity to be achieved.
In an alternative embodiment, the liquid substrate is comprised of the following, at Table 3:
Table 3 Essential Grams Amino Acids Isoleucine 11.25 Leucine 11.25 Methionine 11.25 Phenylalanine 11.25 Threonine 11.25 Tryptophan 11.25 Valine 11.25 Histidine 11.25 Lysine 90 Non-Essential Grams Amino Acids Alanine 2.5 Arginine 2.5 Aspartate 7.5 Glutamate 2.5 Glycine 2.5 Serine 2.5 Praline 90 Phosphates Grams Acetylcholine 6-7 Free Bases Grams Adenosine 13-14 Uridine 13-14 Guanosine 13-14 Cyhdine 13-14 Iridine 13-14 Benzoic Acid 20 Sodium .1-.9 Chloride Sterile water .9-1.2L
Most preferred, the pH of the final solution for the liquid substrate should be 7.45 with a tendency to apply a basic pH.
An additional substrate may be applied, the additional substrate comprised of the following: a mixture of tricalcium phosphate and hydroxyapatite crystals. The tricalcium phosphate is precipitated with CaOH/devil's claw oil, in a preferred embodiment. Optionally, the additional substrate include 50% tricalcium phosphate/devil's claw oil precipitated with 50%
porous hydroxyapatite crystals. The tricalcium phosphate crystals used are granules in the following sizes: 10-50 gm, 50-150 gm, 100-300 gm, 500-1000 inn, 1-3mm and 3-6 mm. The tricalcium phosphate crystals may be dense or porous.
The additional substrate may be comprised of hydroxyapatite crystals of granules containing the following sizes: 10-50 gm, 50-150 gm, 100-300 gm, 500-1000 pun, 1-3mm and 3-6 mm. The hydroxyapatite crystals may be dense or porous.
In the following examples, the conditioner is applied and is rinsed out.
Optionally, the conditioner is left in the sulcus, as the conditioner allowed the micropores within the tooth structures to remain open.
After the conditioner is applied, the sulcus is biostimulated with a laser light. After this occurs, the liquid substrate is applied. Optionally, the additional substrate is applied.
Examples I. Analysis of Tooth #15 at 12 Unique Loci A patient's pocket depths at tooth 15 were measured at 12 separate loci. The root of the tooth was then scaled and planed to remove calculus build up on the root surface. After scaling and planning, bleeding occurs in the sulcus. The sulcus was allowed to air dry and immediately thereafter the conditioner is applied to the sulcus and left for 30 seconds before being rinsed with saline. The tooth was next scaled and planed again to renew blood flow. With blood pooling in the sulcus, the 450 laser tip was placed into the sulcus. The laser light used has a wavelength in the visible portion of the electromagnetic spectrum, between 400nm ¨ 700nm wavelength. The laser was emitted continuously with only intermittent stops for tissue temperature control. The laser was allowed to penetrate the entire sulcus by moving the tip vertically and horizontally throughout the sulcus for 30 second. The laser tip was cut to 450 in the opposite angle for the second pass into the sulcus and 90' for the third pass to allow the laser bean to penetrate the existing periodontium to decontaminate and biostimulate the sulcular contents.
In the meantime, the first substrate and the second substrate were mixed in a glass dish.
Some of the patient's blood that has been treated with the laser light in the sulcus was also mixed in the glass dish. This mixture is then placed immediately into the sulcus upon mixture. Enough of the mixture was placed into the sulcus to fill the sulcus while ensuring the mixture stayed 3 mm below the top of the gingival margin and also remained immersed in blood.
The patient's mouth was kept open for 5 minutes to ensure the newly formed blood clot containing the substrate mixture remained intact.
Treatment was repeated on tooth 15 on four subsequent occasions, at which time the pocket depths at each loci were measured prior to treatment. Measurements are shown in Fig.
11. The data show an increase in calcium density at the specific loci.
IL Analysis of Tooth #12 at 17 Unipue Loci A patient's pocket depths at tooth 28 were measured at 17 separate loci. The treatment disclosed herein was performed on five subsequent occasions, at which time the pocket depths at each loci were measured prior to treatment. Measurements are shown in Fig. 12.
The data show an increase in calcium density across all loci.
III. Analysis of Tooth #2, #3 and #15 at 3 Unique Loci Per Tooth A patient's pocket depths at tooth 2, tooth 3 and tooth 15 were measured at three separate loci per tooth. The treatment disclosed herein was performed 3 months after the initial treatment, at which time the pocket depths at each loci were measured prior to treatment.
Measurements are shown in Fig. 13. The data show a progression of bone generation.
While there have been shown and described and pointed out the fundamental novel features of the invention as applied to the preferred embodiments, it will be understood that the foregoing is considered as illustrative only of the principles of the invention and not intended to be exhaustive or to limit the invention to the precise forms disclosed.
Obvious modifications or variations are possible in light of the above teachings. The embodiments discussed were chosen and described to provide the best illustration of the principles of the invention and its practical application to enable one of ordinary skill in the art to utilize the invention in various embodiments and with various modifications as are suited to the particular use contemplated All such modifications and variations are within the scope of the invention as determined by the appended claims when interpreted in accordance with the breadth to which they are entitled.
The LAPOR protocol is much less invasive than traditional surgery and offers advantages and benefits over its counterpart. Recovery time is much faster because most, if not all, damage to healthy tissue is avoided through the use of more advanced technology.
Because the LAPOR
protocol leaves healthy tissue intact, the height of the gums themselves around the teeth is much better preserved. The LAPOR protocol prevents long junctional epithelium from migrating downwards into the sulcus, thus preserving the tissue height and allowing for the regeneration of the periodontium.
Firstly, the root conditioner is applied to the sulcus. The root conditioner comprises the following at Table 1:
Table 1 Component EDTA 20-25g.
Calcium gluconate 10-20 g.
Methylpara ben .1-.9 g.
Pro pylpa ra be n .01-.1 g.
Ethanolamine 2-8 mis.
Ca rboxymethylce II u lose 2-10 g.
Green food coloring 1-2 drops Sterile water 100 mls.
The conditioner is optionally rinsed out prior to application of additional substrates or laser light. Alternatively, the conditioner is left in the sulcus, with the laser light being applied prior to application of any substrate. In an alternative embodiment, the conditioner is left in with only one substrate applied prior to application of the laser light.
Optionally, the conditioner is left in the sulcus and substrate is added prior to any application of laser light.
The placement of the substrate into the sulcus containing luminesced blood enables the lumineseed blood to coagulate upon the substrate. The substrate contains building blocks for protein synthesis as well as substances used as energy for protein synthesis.
The substrate also contains hard components that are able to be used by the body as a "lattice"
for regeneration.
The substrate also contains a slow release pH increasing agent to increase the pH for optimal regeneration while not "startling" the body such that it will have a negative reaction to the substrate.
Optionally, the liquid substrate is comprised of the following, per 1L of solution, at Table 2:
Table 2 Essential %
Amino Acids Isoleucine 1.125 Leucine 1.125 Methionine 1.125 Phenylalanine 1.125 Threonine 1.125 Tryptophan 1.125 Valine 1.125 Histidine 1.125 Lysine 9 Non Essential %
Amino Acids Alanine 0.25 Arginine 0.25 Aspartate 0.75 Glutamate 0.25 Glycine 0.25 Serine 0.25 Proline 9 Phosphates %
ADP 0.667 ATP 0.667 Acetylcholine 0.667 Free Bases %
Adenosine 1.725 Uridine 1.725 Guanosine 1.725 Cytidine 1.725 Benzoic Acid 1 Sodium 1.1 Chloride Sterile water 60 Total: 100 Optionally, the total sterile water component is adjusted 20% up or down, depending on the desired viscosity to be achieved.
In an alternative embodiment, the liquid substrate is comprised of the following, at Table 3:
Table 3 Essential Grams Amino Acids Isoleucine 11.25 Leucine 11.25 Methionine 11.25 Phenylalanine 11.25 Threonine 11.25 Tryptophan 11.25 Valine 11.25 Histidine 11.25 Lysine 90 Non-Essential Grams Amino Acids Alanine 2.5 Arginine 2.5 Aspartate 7.5 Glutamate 2.5 Glycine 2.5 Serine 2.5 Praline 90 Phosphates Grams Acetylcholine 6-7 Free Bases Grams Adenosine 13-14 Uridine 13-14 Guanosine 13-14 Cyhdine 13-14 Iridine 13-14 Benzoic Acid 20 Sodium .1-.9 Chloride Sterile water .9-1.2L
Most preferred, the pH of the final solution for the liquid substrate should be 7.45 with a tendency to apply a basic pH.
An additional substrate may be applied, the additional substrate comprised of the following: a mixture of tricalcium phosphate and hydroxyapatite crystals. The tricalcium phosphate is precipitated with CaOH/devil's claw oil, in a preferred embodiment. Optionally, the additional substrate include 50% tricalcium phosphate/devil's claw oil precipitated with 50%
porous hydroxyapatite crystals. The tricalcium phosphate crystals used are granules in the following sizes: 10-50 gm, 50-150 gm, 100-300 gm, 500-1000 inn, 1-3mm and 3-6 mm. The tricalcium phosphate crystals may be dense or porous.
The additional substrate may be comprised of hydroxyapatite crystals of granules containing the following sizes: 10-50 gm, 50-150 gm, 100-300 gm, 500-1000 pun, 1-3mm and 3-6 mm. The hydroxyapatite crystals may be dense or porous.
In the following examples, the conditioner is applied and is rinsed out.
Optionally, the conditioner is left in the sulcus, as the conditioner allowed the micropores within the tooth structures to remain open.
After the conditioner is applied, the sulcus is biostimulated with a laser light. After this occurs, the liquid substrate is applied. Optionally, the additional substrate is applied.
Examples I. Analysis of Tooth #15 at 12 Unique Loci A patient's pocket depths at tooth 15 were measured at 12 separate loci. The root of the tooth was then scaled and planed to remove calculus build up on the root surface. After scaling and planning, bleeding occurs in the sulcus. The sulcus was allowed to air dry and immediately thereafter the conditioner is applied to the sulcus and left for 30 seconds before being rinsed with saline. The tooth was next scaled and planed again to renew blood flow. With blood pooling in the sulcus, the 450 laser tip was placed into the sulcus. The laser light used has a wavelength in the visible portion of the electromagnetic spectrum, between 400nm ¨ 700nm wavelength. The laser was emitted continuously with only intermittent stops for tissue temperature control. The laser was allowed to penetrate the entire sulcus by moving the tip vertically and horizontally throughout the sulcus for 30 second. The laser tip was cut to 450 in the opposite angle for the second pass into the sulcus and 90' for the third pass to allow the laser bean to penetrate the existing periodontium to decontaminate and biostimulate the sulcular contents.
In the meantime, the first substrate and the second substrate were mixed in a glass dish.
Some of the patient's blood that has been treated with the laser light in the sulcus was also mixed in the glass dish. This mixture is then placed immediately into the sulcus upon mixture. Enough of the mixture was placed into the sulcus to fill the sulcus while ensuring the mixture stayed 3 mm below the top of the gingival margin and also remained immersed in blood.
The patient's mouth was kept open for 5 minutes to ensure the newly formed blood clot containing the substrate mixture remained intact.
Treatment was repeated on tooth 15 on four subsequent occasions, at which time the pocket depths at each loci were measured prior to treatment. Measurements are shown in Fig.
11. The data show an increase in calcium density at the specific loci.
IL Analysis of Tooth #12 at 17 Unipue Loci A patient's pocket depths at tooth 28 were measured at 17 separate loci. The treatment disclosed herein was performed on five subsequent occasions, at which time the pocket depths at each loci were measured prior to treatment. Measurements are shown in Fig. 12.
The data show an increase in calcium density across all loci.
III. Analysis of Tooth #2, #3 and #15 at 3 Unique Loci Per Tooth A patient's pocket depths at tooth 2, tooth 3 and tooth 15 were measured at three separate loci per tooth. The treatment disclosed herein was performed 3 months after the initial treatment, at which time the pocket depths at each loci were measured prior to treatment.
Measurements are shown in Fig. 13. The data show a progression of bone generation.
While there have been shown and described and pointed out the fundamental novel features of the invention as applied to the preferred embodiments, it will be understood that the foregoing is considered as illustrative only of the principles of the invention and not intended to be exhaustive or to limit the invention to the precise forms disclosed.
Obvious modifications or variations are possible in light of the above teachings. The embodiments discussed were chosen and described to provide the best illustration of the principles of the invention and its practical application to enable one of ordinary skill in the art to utilize the invention in various embodiments and with various modifications as are suited to the particular use contemplated All such modifications and variations are within the scope of the invention as determined by the appended claims when interpreted in accordance with the breadth to which they are entitled.
Claims (14)
1. A substrate mixture for the treatment of gum disease, wherein the substrate mixtures is comprised of:
a) a first substrate; and b) a second substrate.
a) a first substrate; and b) a second substrate.
2. The substrate mixture of claim 1, wherein the first substrate is comprised of:
a) 60% sterile water b) 1.1% sodium chloride;
c) 1% benzoic acid;
d) 9% Lysine;
e) 9% Proline;
f) 9% essential amino acids, wherein the essential amino acids include equal parts Isoleucine, Leucine, Methionine, Phenylalanine, Threonine, Tryptophan, Valine and Histadine;
g) 2% non-essential amino acids, wherein the non-essential amino acids include equal parts Alanine, Arginine, Aspartate, Glutamate, Glycine and Serine;
h) 2% phosphates, wherein the phosphates include equal parts adenosine diphospate (ADP), adenosine triphosphate (ATP), and Acetylcholine; and i) 6.9% free bases, wherein the free bases include equal parts adenosine, uridine, guanosine, and cytidine.
a) 60% sterile water b) 1.1% sodium chloride;
c) 1% benzoic acid;
d) 9% Lysine;
e) 9% Proline;
f) 9% essential amino acids, wherein the essential amino acids include equal parts Isoleucine, Leucine, Methionine, Phenylalanine, Threonine, Tryptophan, Valine and Histadine;
g) 2% non-essential amino acids, wherein the non-essential amino acids include equal parts Alanine, Arginine, Aspartate, Glutamate, Glycine and Serine;
h) 2% phosphates, wherein the phosphates include equal parts adenosine diphospate (ADP), adenosine triphosphate (ATP), and Acetylcholine; and i) 6.9% free bases, wherein the free bases include equal parts adenosine, uridine, guanosine, and cytidine.
3. The substrate mixture of claim 1, wherein the second substrate is comprised of:
a) tricalcium phosphate, wherein the tricalcium phosphate is precipitated in calcium hydroxide and Claw oil; and b) hydroxyapatite crystals.
a) tricalcium phosphate, wherein the tricalcium phosphate is precipitated in calcium hydroxide and Claw oil; and b) hydroxyapatite crystals.
4. A method for treating gum disease and associated bacteria in a periodontal pocket, the periodontal pocket being defined by opposing root and periodontium surfaces that are detached from one another, the method comprising the following steps:
Step A: scaling the root surface for detaching bacteria therefrom while simultaneously stimulating the periodontium surface for opening capillaries therein; then Step B: passing a beam of laser light over the root surface for killing bacteria and disinfecting the root surface;
Step C: passing a beam of laser light into the opposing periodontium surface for heating and biostimulating the opened capillaries of said Step A in preparation for bleeding therefrom; then Step D: after heating and biostimulating the opened capillaries in said Step C, scaling the root surface again while simultaneously stimulating the periodontium surface for inducing blood flow and bleeding therefrom for displacing bacteria from the periodontal pocket and filling the periodontal pocket with blood;
Step E: prior to blood clot formation, placing and maintaining a substrate mixture into the periodontal pocket for facilitating and stabilizing blood clot formation therein; and then Step F: maintaining the substrate mixture of said Step E intact within the periodontal pocket until blood clot formation has occurred;
whereby treatment of the gum disease in the periodontal pocket is facilitated by the disinfection of the root surface by scaling and passing a beam of laser light thereover, by the displacement of bacteria from the periodontal pocket by bleeding from the periodontium, and by the subsequent clot formation in the presence of the substrate mixture, clot maintenance, and clot induced healing with the substrate within the periodontal pocket.
Step A: scaling the root surface for detaching bacteria therefrom while simultaneously stimulating the periodontium surface for opening capillaries therein; then Step B: passing a beam of laser light over the root surface for killing bacteria and disinfecting the root surface;
Step C: passing a beam of laser light into the opposing periodontium surface for heating and biostimulating the opened capillaries of said Step A in preparation for bleeding therefrom; then Step D: after heating and biostimulating the opened capillaries in said Step C, scaling the root surface again while simultaneously stimulating the periodontium surface for inducing blood flow and bleeding therefrom for displacing bacteria from the periodontal pocket and filling the periodontal pocket with blood;
Step E: prior to blood clot formation, placing and maintaining a substrate mixture into the periodontal pocket for facilitating and stabilizing blood clot formation therein; and then Step F: maintaining the substrate mixture of said Step E intact within the periodontal pocket until blood clot formation has occurred;
whereby treatment of the gum disease in the periodontal pocket is facilitated by the disinfection of the root surface by scaling and passing a beam of laser light thereover, by the displacement of bacteria from the periodontal pocket by bleeding from the periodontium, and by the subsequent clot formation in the presence of the substrate mixture, clot maintenance, and clot induced healing with the substrate within the periodontal pocket.
5. The method of claim 4, wherein the substrate mixture is comprised of a first substrate and a second substrate.
6. The method of claim 5, wherein the first substrate is comprised of:
a) 60% sterile water b) 1.1% sodium chloride;
c) 1% benzoic acid;
d) 9% Lysine;
e) 9% Proline;
f) 9% essential amino acids, wherein the essential amino acids include equal parts Isoleucine, Leucine, Methionine, Phenylalanine, Threonine, Tryptophan, Valine and Histadine;
g) 2% non-essential amino acids, wherein the non-essential amino acids include equal parts Alanine, Arginine, Aspartate, Glutamate, Glycine and Serine;
h) 2% phosphates, wherein the phosphates include equal parts adenosine diphospate (ADP), adenosine triphosphate (ATP), and Acetylcholine; and i) 6.9% free bases, wherein the free bases include equal parts adenosine, uridine, guanosine, and cytidine.
a) 60% sterile water b) 1.1% sodium chloride;
c) 1% benzoic acid;
d) 9% Lysine;
e) 9% Proline;
f) 9% essential amino acids, wherein the essential amino acids include equal parts Isoleucine, Leucine, Methionine, Phenylalanine, Threonine, Tryptophan, Valine and Histadine;
g) 2% non-essential amino acids, wherein the non-essential amino acids include equal parts Alanine, Arginine, Aspartate, Glutamate, Glycine and Serine;
h) 2% phosphates, wherein the phosphates include equal parts adenosine diphospate (ADP), adenosine triphosphate (ATP), and Acetylcholine; and i) 6.9% free bases, wherein the free bases include equal parts adenosine, uridine, guanosine, and cytidine.
7. The method of claim 5, wherein the second substrate is comprised of:
a) tricalcium phosphate, wherein the tricalcium phosphate is precipitated in calcium hydroxide and Claw oil; and b) hydroxyapatite crystals.
a) tricalcium phosphate, wherein the tricalcium phosphate is precipitated in calcium hydroxide and Claw oil; and b) hydroxyapatite crystals.
8. The method of claim 4 wherein further in said Step F, the substrate mixture is maintained intact in the periodontal pocket for at least 5 minutes.
9. The method of claim 4, wherein in further in said Step C, the laser light employed is of a type absorbed by haemoglobin and/or melanin and with sufficient duration for heating and biostimulating the opened capillaries.
10. The method of claim 4, wherein further:
in said Step A, the stimulation optionally induces bleeding and blood flow;
and in said Step D, the bleeding and blood flow is enhanced over bleeding and blood flow in said Step A due to the heating and biostimulating of the opened capillaries in said Step C;
whereby the displacement of bacteria from the periodontal pocket in said Step D is enhanced as compared to said Step A.
in said Step A, the stimulation optionally induces bleeding and blood flow;
and in said Step D, the bleeding and blood flow is enhanced over bleeding and blood flow in said Step A due to the heating and biostimulating of the opened capillaries in said Step C;
whereby the displacement of bacteria from the periodontal pocket in said Step D is enhanced as compared to said Step A.
11. The method of claim 4 wherein the scaling in step A is selected from the group consisting of ultrasonic scaling, hand tool scaling, and both ultrasonic and hand tool scaling.
12. The method of claim 4, wherein the method further comprises the following step:
Prior to said Step A, determining the depth of the periodontal pocket.
Prior to said Step A, determining the depth of the periodontal pocket.
13. The method of claim 4, wherein prior to Step A, the tooth is conditioned with an EDTA
gel for at least 30 seconds.
gel for at least 30 seconds.
14. The method of claim 13, wherein the EDTA gel is comprised of:
a) sterile water;
b) edetate disodium;
c) calcium gluconate;
d) methylparaben;
e) propylparaben;
f) ethanolamine;
g) carboxymethylcellulose; and f) green food coloring.
a) sterile water;
b) edetate disodium;
c) calcium gluconate;
d) methylparaben;
e) propylparaben;
f) ethanolamine;
g) carboxymethylcellulose; and f) green food coloring.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/864,226 US9180319B2 (en) | 2011-04-01 | 2013-04-16 | Laser assisted periodontium and osseus regeneration protocol |
US13/864,226 | 2013-04-16 | ||
PCT/US2014/034366 WO2014172459A2 (en) | 2013-04-16 | 2014-04-16 | Laser assisted periodontium and osseus regeneration protocol |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2909645A1 true CA2909645A1 (en) | 2014-10-23 |
Family
ID=51731975
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2909645A Abandoned CA2909645A1 (en) | 2013-04-16 | 2014-04-16 | Laser assisted periodontium and osseus regeneration protocol |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP2986250A4 (en) |
JP (1) | JP6399561B2 (en) |
KR (1) | KR20160013020A (en) |
CN (1) | CN105358122B (en) |
AU (2) | AU2014254001B2 (en) |
CA (1) | CA2909645A1 (en) |
WO (1) | WO2014172459A2 (en) |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3950529A (en) * | 1975-02-03 | 1976-04-13 | Massachusetts General Hospital | Amino acid formulations for patients with liver disease and method of using same |
US5632972A (en) * | 1994-06-30 | 1997-05-27 | Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. | Method for treating gingival and periodontal tissues |
EP1255576B1 (en) * | 1999-12-09 | 2003-08-20 | Biosyntech Canada Inc. | Mineral-polymer hybrid composition |
DE10102372A1 (en) * | 2001-01-19 | 2002-08-14 | Merz & Co Gmbh & Co | Mixture for the treatment of inflammatory dental diseases and for use as a root canal filling material |
US8491936B2 (en) * | 2005-03-16 | 2013-07-23 | North Carolina State University | Functionally graded biocompatible coating and coated implant |
JP2009518064A (en) * | 2005-11-30 | 2009-05-07 | ノミール・メディカル・テクノロジーズ・インコーポレーテッド | Optical therapy treatment device |
ES2397890B1 (en) * | 2011-03-25 | 2014-02-07 | Lipotec, S.A. | USEFUL PEPTIDES IN THE TREATMENT AND / OR CARE OF SKIN AND / OR MUCOSES AND ITS USE IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS. |
US9180319B2 (en) * | 2011-04-01 | 2015-11-10 | Margaret V. Kalmeta | Laser assisted periodontium and osseus regeneration protocol |
US11730760B2 (en) * | 2011-04-01 | 2023-08-22 | The Bioregentech Institute, Inc. | Laser assisted wound healing protocol and system |
US20120251972A1 (en) * | 2011-04-01 | 2012-10-04 | Margaret Violett Kalmeta | Laser Assisted Periodontium And Osseus Regeneration Protocol |
-
2014
- 2014-04-16 CA CA2909645A patent/CA2909645A1/en not_active Abandoned
- 2014-04-16 WO PCT/US2014/034366 patent/WO2014172459A2/en active Application Filing
- 2014-04-16 KR KR1020157032637A patent/KR20160013020A/en not_active Application Discontinuation
- 2014-04-16 JP JP2016509068A patent/JP6399561B2/en active Active
- 2014-04-16 AU AU2014254001A patent/AU2014254001B2/en active Active
- 2014-04-16 EP EP14785561.3A patent/EP2986250A4/en not_active Withdrawn
- 2014-04-16 CN CN201480032289.3A patent/CN105358122B/en active Active
-
2020
- 2020-01-22 AU AU2020200444A patent/AU2020200444B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
CN105358122B (en) | 2018-06-01 |
KR20160013020A (en) | 2016-02-03 |
CN105358122A (en) | 2016-02-24 |
EP2986250A2 (en) | 2016-02-24 |
JP6399561B2 (en) | 2018-10-03 |
WO2014172459A2 (en) | 2014-10-23 |
AU2014254001A1 (en) | 2015-11-26 |
AU2020200444A1 (en) | 2020-02-13 |
AU2014254001B2 (en) | 2019-10-24 |
JP2016524591A (en) | 2016-08-18 |
EP2986250A4 (en) | 2017-03-22 |
AU2020200444B2 (en) | 2022-05-26 |
WO2014172459A3 (en) | 2015-01-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9180319B2 (en) | Laser assisted periodontium and osseus regeneration protocol | |
US11730760B2 (en) | Laser assisted wound healing protocol and system | |
Trowbridge et al. | A review of current approaches to in-office management of tooth hypersensitivity | |
JP5659147B2 (en) | Remineralization of calcified tissue | |
US11684797B2 (en) | Laser assisted wound healing protocol and system | |
Taniguchi et al. | A Novel Surgical Procedure for Er: YAG Laser-Assisted Periodontal Regenerative Therapy: Case Series. | |
US11745026B2 (en) | Laser assisted wound healing protocol and system | |
AU2016353150B2 (en) | Laser assisted wound healing protocol and system | |
US20120251972A1 (en) | Laser Assisted Periodontium And Osseus Regeneration Protocol | |
AU2020200444B2 (en) | Laser assisted periodontium and osseus regeneration protocol | |
Curylofo-Zotti et al. | The combined use of sodium fluoride and Er: YAG laser to control the progression of enamel caries | |
Fatima et al. | Minimal invasive dentistry: A review | |
US11654293B2 (en) | Laser assisted wound healing protocol and system | |
Badr et al. | Remineralizing Effect of Diode Laser and Amelogenin Peptide on Early Enamel Carious Lesion | |
EP3538001A1 (en) | Laser assisted wound healing protocol and system | |
RU2181989C1 (en) | Method for treating periimplantitis | |
RU2179417C1 (en) | Surgical method for treating alveolar bone defects on the perodontitis background | |
JP2023180375A (en) | Non-surgical periodontal regeneration therapy | |
Kawle | A Comparative Evaluation of the Combined Occluding Effect of Sodium Fluoride Varnish and Er: Yag Laser Irradiation on Dentinal Tubules-A Confocal Laser Scanning Microscope and Scanning Electron Microscope-An in Vitro Study | |
Watanabe | LASER PERIODONTICS | |
BOSTANCI et al. | New attachment formation following periodontal surgery in a dog | |
Khan et al. | A Comparison of bioresorbable membrane alone or in Combination with tetracycline root conditioning in treating intrabony defects | |
Elshehawy | Effect of low-level laser therapy on the rate of leveling and alignment of the lower anterior teeth: A randomized controlled clinical study | |
Singh et al. | List of Articles Pages No. | |
Dwivedi et al. | Comparative evaluation of efficacy of diode laser and two commercially available desensitizing toothpastes for dentinal tubular occlusion: A scanning electron microscope (SEM) study |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |
Effective date: 20180130 |
|
EEER | Examination request |
Effective date: 20180130 |
|
EEER | Examination request |
Effective date: 20180130 |
|
FZDE | Discontinued |
Effective date: 20230602 |